Christine A Kiire1, Rosalind M K Stewart2,3, Sathish Srinivasan4,5, Heinrich Heimann2,3, Stephen B Kaye2,3, Baljean Dhillon6. 1. Oxford Eye Hospital, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. christine.kiire@ouh.nhs.uk. 2. St Paul's Eye Unit, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK. 3. Department of Eye and Vision Science, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK. 4. Department of Ophthalmology, University Hospital Ayr, Ayr, UK. 5. University of Glasgow, Glasgow, Scotland, UK. 6. School of Clinical Sciences, University of Edinburgh, Edinburgh, UK.
Abstract
PURPOSE: To describe the incidence, associations and outcomes of ocular surface squamous neoplasia (OSSN) in the United Kingdom. METHODS: Prospective, observational study of every new case of OSSN reported via the British Ophthalmological Surveillance Unit reporting scheme over a 12-month period. Cases were followed up for 12 months. RESULTS: The reported incidence of OSSN was 0.53 cases/million/year (conjunctival intraepithelial neoplasia: 0.43 cases/million/year; squamous cell carcinoma: 0.08 cases/million/year). Eighty-five per cent of affected patients were male, 97% were Caucasian, and the mean age at presentation was 67.9 (±12.8) years. Information on potential underlying risk factors was frequently unknown. The most commonly affected sites were the limbus and the nasal and temporal bulbar conjunctivae. Most patients presented with a visual acuity of 6/9 or better, without symptoms of pain or visual loss. Excision (with or without additional treatment) was the most common first-line treatment and interferon (with or without additional treatment) was the most common second-line treatment, although management varied widely. Complications of treatment were rare but occasionally severe. Recurrence within 12 months of follow-up occurred in at least 6% of patients. CONCLUSION: Although subject to reporting bias, these data suggest that there has not been a significant change in the incidence of OSSN in the United Kingdom, or its demographic profile, since 1996. The broad range of management approaches identified in this study reflect a lack of consensus as to the optimal referral and treatment pathways.
PURPOSE: To describe the incidence, associations and outcomes of ocular surface squamous neoplasia (OSSN) in the United Kingdom. METHODS: Prospective, observational study of every new case of OSSN reported via the British Ophthalmological Surveillance Unit reporting scheme over a 12-month period. Cases were followed up for 12 months. RESULTS: The reported incidence of OSSN was 0.53 cases/million/year (conjunctival intraepithelial neoplasia: 0.43 cases/million/year; squamous cell carcinoma: 0.08 cases/million/year). Eighty-five per cent of affected patients were male, 97% were Caucasian, and the mean age at presentation was 67.9 (±12.8) years. Information on potential underlying risk factors was frequently unknown. The most commonly affected sites were the limbus and the nasal and temporal bulbar conjunctivae. Most patients presented with a visual acuity of 6/9 or better, without symptoms of pain or visual loss. Excision (with or without additional treatment) was the most common first-line treatment and interferon (with or without additional treatment) was the most common second-line treatment, although management varied widely. Complications of treatment were rare but occasionally severe. Recurrence within 12 months of follow-up occurred in at least 6% of patients. CONCLUSION: Although subject to reporting bias, these data suggest that there has not been a significant change in the incidence of OSSN in the United Kingdom, or its demographic profile, since 1996. The broad range of management approaches identified in this study reflect a lack of consensus as to the optimal referral and treatment pathways.
Authors: R Masanganise; S Rusakaniko; R Makunike; M Hove; E Chokunonga; M Z Borok; B G Mauchaza; Mz Chirenje; V N Masanganise; T Magure Journal: Cent Afr J Med Date: 2008 May-Aug
Authors: Priyadharsini Nagarajan; Christian El-Hadad; Stephen K Gruschkus; Jing Ning; Courtney W Hudgens; Oded Sagiv; Neil Gross; Michael T Tetzlaff; Bita Esmaeli Journal: Invest Ophthalmol Vis Sci Date: 2019-05-01 Impact factor: 4.799